Clinical Trials Directory

Trials / Completed

CompletedNCT02455401

Effect of Remifentanil on Postoperative Vomiting in Pediatric Strabismus Surgery

Effect of Remifentanil on Postoperative Vomiting in Children Undergoing Strabismus Surgery During Sevoflurane Anesthesia

Status
Completed
Phase
N/A
Study type
Interventional
Enrollment
60 (actual)
Sponsor
Inje University · Academic / Other
Sex
All
Age
3 Years – 6 Years
Healthy volunteers
Not accepted

Summary

The purpose of this study is to compare the effect of remifentanil on postoperative vomiting in children undergoing strabismus surgery during sevoflurane anesthesia.

Detailed description

Children undergoing strabismus surgery frequently experience postoperative vomiting (POV) that results in dehydration, aspiration pneumonia, bleeding, delayed hospital discharge, as well as decreased parental satisfaction and an unpleasant experience for the pediatric patients. Although administration of perioperative opioids increases POV incidence, remifentanil has less affect the incidence of POV than other opioids such as fentanyl. However, there are few study that evaluate the effects of remifentanil on the incidence of POV. Therefore, the investigators will conducted the study that the effects of remifentanil on the incidence of POV in children undergoing strabismus surgery during sevoflurane anesthesia. One hundred five children from 3 to 6 yr of age, ASA physical status 1 or 2 were assigned randomly selected to one of three groups: high dose remifentanil group (bolus 1.0 mcg/kg; infusion 0.1 mcg/kg/min), low remifentanil group (bolus 0.5 mcg/kg; infusion 0.1 mcg/kg/min), or no remifentanil group (no remifentanil administration). Primary endpoint, the incidence of POV for 24 hours postoperatively, will be compared between three study groups.

Conditions

Interventions

TypeNameDescription
DRUGHigh dose remifentanilIntervention: continuously intravenous infusion of remifentanil 0.1 mcg/kg/min after bolus injection of remifentanil 1.0 mcg/kg for 2 minutes
DRUGLow dose remifentanilIntervention: continuously intravenous infusion of remifentanil 0.1 mcg/kg/min after bolus injection of remifentanil 0.5 mcg/kg for 2 minutes
DRUGNo remifentanilIntervention: no remifentanil will be administrated

Timeline

Start date
2015-05-01
Primary completion
2017-11-01
Completion
2017-11-01
First posted
2015-05-27
Last updated
2017-11-14

Locations

1 site across 1 country: South Korea

Source: ClinicalTrials.gov record NCT02455401. Inclusion in this directory is not an endorsement.